Pharmaceutical giant Johnson & Johnson says it’s currently unable to provide a sales forecast for its Covid-19 vaccine. According to the firm, vaccine hesitancy in low-income countries, coupled with existing low demand in wealthier nations, has led to a surplus of stock. J&J had previously forecast sales of up to US$3.5 billion for this year, according to a Reuters report. Demand for the J&J single-dose vaccine has been affected by reports of rare but potentially fatal blood clots linked to the jab, along with manufacturing hiccups and concerns about the vaccine’s efficacy when compared to others. The J&J vaccine makes […]
The story Low demand, supply surplus leads J&J to suspend sales forecast of Covid vaccine as seen on Thaiger News.